NAFLD & NASH in 2020: Where We Are Now, and Where We Are Headed
Dates and Times
Start: 1/29/2020 7:45 AM
End: 1/29/2020 8:45 AM
The participant should be able to identify and recognize the risk factors and comorbidities that are associated with NAFLD.
The participant should have a better understanding of the modalities available to diagnose NAFLD and evaluate for advanced fibrosis and cirrhosis.
The participant should be aware of the currently approved therapies for NAFLD/NASH, and which patients qualify for treatment.
The participant should have further knowledge of the different medical therapies undergoing clinical trials for NASH as well as the therapeutic targets of those medications.
Lecture Hall 2
101 Nicolls Road
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.